Poster: CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览5

暂无评分

摘要

All-oral, once-daily, fixed-duration Ibr+Ven demonstrated superior uMRD responses that were deeper and better sustained post-treatment versus Clb+O in older adult or unfit patients with previously untreated CLL.

查看译文

关键词

CLL,minimal residual disease,MRD,ibrutinib,venetoclax,GLOW,chronic lymphocytic leukemia,fixed-duration,Phase III

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要